Incheon Technopark (Incheon TP) announced on the 23rd that two promising AI and bio startups, Soro and Imitascience, have each successfully secured 200 million won in funding for a total of 400 million won.


This investment was made through the Incheon Innovation Fund, which was established jointly by Incheon TP and Incheon Metropolitan City. The sub-fund operated by Tab Angel Partners invested 200 million won in Soro, while the sub-fund jointly managed by TBG Partners and J&P Medi Partners invested 200 million won in Imitascience.


Soro is a company that develops AI solutions to integrate the management of injection molding facilities and analyze the causes of defects, while Imitascience is engaged in developing a new drug development platform based on organ-on-a-chip, a biomimetic device.


AI and bio promising companies, Seoro and Imitascience, each secured an investment of 200 million won through the Incheon Innovation Fund. Provided by Incheon Technopark

AI and bio promising companies, Seoro and Imitascience, each secured an investment of 200 million won through the Incheon Innovation Fund. Provided by Incheon Technopark

View original image

With this investment, Soro plans to further advance its AI analysis technology and applicability in manufacturing sites, while Imitascience aims to enhance its organ-on-a-chip platform to strengthen its competitiveness in next-generation preclinical testing technologies.



An official from Incheon TP stated, "This achievement showcases how discovering and fostering companies through investment by the Incheon Innovation Fund can lead to actual investments," and added, "We will continue to collaborate with local private investment institutions to support investment attraction and subsequent growth for companies with high growth potential."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing